- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07589062
Healthy Eating and Active Living for People Living With Multiple Sclerosis (HEAL MS): A Lifestyle Program for People With Multiple Sclerosis (HEAL-MS)
HEAL MS: A Culturally Adapted Lifestyle Medicine Intervention Targeting Metabolic and Immune Dysregulation in Multiple Sclerosis Using Multi-Omics Profiling
The goal of this clinical trial is to learn whether a structured lifestyle program can improve health and wellbeing in people living with multiple sclerosis (MS). The program focuses on four areas: nutrition, physical activity, sleep, and stress management. The study will also examine how lifestyle changes affect biological markers related to inflammation, metabolism, and immune function.
The main questions the study aims to answer are:
Can a 12-week lifestyle program improve fatigue, physical function, sleep, and quality of life in people with MS? Do lifestyle changes influence biological markers related to inflammation, metabolism, and mitochondrial function?
Participants will first complete a 12-week observation period to measure their usual lifestyle and health. After this, they will take part in the 12-week HEAL MS lifestyle program.
Participants will:
Attend four assessment visits at Yas Clinic (baseline, before the intervention, after the intervention, and three months later) Participate in two supervised online exercise sessions per week during the 12-week program Follow a structured nutrition plan, with meals provided during the first two weeks Use a mobile application to log daily habits related to exercise, nutrition, sleep, and stress Complete questionnaires and physical tests and provide blood, saliva, and stool samples during assessment visits
Researchers will analyze these data to understand whether lifestyle interventions can support symptom management and overall health in people living with MS.
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system characterized by neurodegeneration, demyelination, and progressive disability. Although current treatments primarily focus on immune suppression, growing evidence indicates that non-immune mechanisms, including mitochondrial dysfunction, metabolic imbalance, and chronic systemic inflammation, play a significant role in disease progression and symptom burden. Multi-omics studies have identified disruptions in mitochondrial proteins, lipid and amino acid metabolism, and inflammatory signaling pathways in individuals with MS, suggesting that systemic metabolic processes contribute to disease activity and may represent modifiable therapeutic targets.
HEAL MS (Healthy Eating and Active Living for Multiple Sclerosis) was developed to address these upstream biological drivers through a structured lifestyle intervention integrating nutrition, physical activity, sleep optimization, and stress regulation. The program is culturally adapted for the UAE population and delivered through a hybrid model combining in-person onboarding and digital support via a bilingual (Arabic-English) mobile application that facilitates behavioral tracking, education, and participant engagement.
This study is a 24-month pilot interventional study designed to evaluate the feasibility, acceptability, and biological impact of the HEAL MS program in individuals with relapsing-remitting or progressive MS. Thirty participants will be recruited from collaborating MS clinics. The study uses a within-subject design consisting of a 12-week observation (control) period followed by a 12-week lifestyle intervention. Assessments are conducted at four timepoints: baseline, pre-intervention, post-intervention, and three months after completion of the intervention. This design allows each participant to serve as their own control, improving statistical sensitivity and reducing inter-individual variability.
The intervention targets four behavioral domains. Adaptive movement training consists of supervised small-group sessions conducted twice weekly using functional resistance exercises based on bodyweight, resistance bands, and suspension training. Exercises are designed to improve strength, neuromuscular coordination, and mitochondrial resilience while remaining scalable to accommodate MS-related fatigue and mobility limitations. The nutrition component emphasizes anti-inflammatory, nutrient-dense whole foods with a macronutrient distribution of approximately 40% carbohydrates, 30% protein, and 30% fat. Personalized calorie targets are calculated using the Mifflin-St Jeor equation, and participants receive meal delivery during the initial two weeks to facilitate adherence before transitioning to guided self-preparation. Sleep optimization focuses on circadian-aligned behavioral strategies such as consistent sleep schedules, screen-light reduction, and timing of meals and exercise. Stress regulation includes daily breath-based practices, mindfulness exercises, and vagal nerve-stimulating techniques designed to support autonomic balance. Participant engagement and adherence are supported through daily behavioral tracking using the mobile application.
The study integrates biological, clinical, and behavioral outcomes to evaluate the mechanistic impact of the intervention. Blood samples collected at each assessment will undergo routine clinical chemistry testing and high-resolution molecular profiling. Proteomic analysis will be performed using the Olink Reveal platform, enabling multiplex quantification of over 1,000 plasma proteins related to immune signaling, inflammation, oxidative stress, and metabolic regulation. Metabolomic profiling will be conducted using nuclear magnetic resonance spectroscopy to quantify approximately 250 circulating metabolic biomarkers related to mitochondrial function and systemic metabolism.
Additional outcome measures include body composition assessment using multi-frequency bioelectrical impedance analysis, validated functional performance tests (6-minute step test, five-times-sit-to-stand test, and grip strength), and psychometric instruments assessing fatigue, mood, sleep quality, cognitive performance, and quality of life. Wearable monitoring devices will be used to capture sleep duration, activity levels, and heart rate variability as indicators of physiological recovery and autonomic regulation.
By integrating behavioral intervention with high-resolution molecular profiling, HEAL MS aims to generate mechanistic insight into how lifestyle modification influences metabolic, inflammatory, and mitochondrial pathways in MS. Findings from this pilot study will inform the feasibility and design of larger randomized trials investigating lifestyle-based strategies as complementary approaches to disease management.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Natascha Enriquez, MSc
- Telefonnummer: +971501821961
- E-mail: natasha.enriquez@nyu.edu
Undersøgelse Kontakt Backup
- Navn: Youssef Idaghdour, Professor
- Telefonnummer: +971561845775
- E-mail: yi3@nyu.edu
Studiesteder
-
-
-
Abu Dhabi, Forenede Arabiske Emirater
- Yas Clinic
-
Kontakt:
- Lev Brylev, MD, PhD
- Telefonnummer: +971502377993
- E-mail: lev.brylev@adscc.ae
-
Kontakt:
- Ruqqia Mir, MD
- Telefonnummer: +971553676270
- E-mail: ruqqia.m@adscc.ae
-
Underforsker:
- Lev Brylev, MD, PhD
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- Confirmed MS diagnosis (McDonald criteria)
- EDSS score ≤ 6.5 (i.e., ambulatory with or without assistance)
- Stable disease-modifying therapy for ≥ 3 months
- Age 18-50
- Proficiency in English or Arabic
- Clearance to participate in a structured exercise program
- Ability to walk, sit and stand independently, and perform light-to-moderate movement patterns, even with modifications
- Ability and digital literacy to interact with the bilingual HEAL MS mobile app and
- Access to a computer for participation in online sessions
Exclusion Criteria:
- Significant cognitive impairment affecting app use and comprehension of the intervention
- MS relapse within the past 3 months
- Pregnancy or planned pregnancy
- Unmanaged psychiatric disorders
- Other immune-related or chronic inflammatory or metabolic diseases
- Concurrent enrollment in another lifestyle intervention
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Støttende pleje
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: HEAL MS Lifestyle Intervention
Participants first complete a 12-week observation period during which they maintain their usual lifestyle.
This is followed by a 12-week HEAL MS lifestyle intervention targeting four domains: adaptive movement, anti-inflammatory nutrition, sleep optimization, and stress regulation.
The movement component includes twice-weekly supervised online group exercise sessions using scalable functional exercises.
The nutrition component provides personalized meal plans with two weeks of meal delivery to support adherence.
Sleep and stress modules include circadian hygiene strategies, breathwork, and mindfulness practices.
Participants track daily behaviors, wellbeing, and optional wearable data through a bilingual mobile application.
Assessments including blood sampling, body composition, functional fitness testing, and questionnaires are conducted at baseline, pre-intervention, post-intervention, and three months post-intervention.
|
The intervention is a 12-week multi-domain lifestyle program.
It targets four behavioral domains: physical activity, nutrition, sleep, and stress regulation.
Participants attend twice-weekly supervised online exercise sessions using scalable functional movements performed with bodyweight, resistance bands, and suspension training.
The nutrition component provides individualized meal plans based on maintenance calories, emphasizing anti-inflammatory, whole-food nutrition with a macronutrient distribution of approximately 40% carbohydrates, 30% protein, and 30% fat.
During the first two weeks, meals are delivered to support adherence.
Sleep optimization focuses on circadian-aligned behaviors such as consistent sleep timing and reduced evening light exposure.
Stress regulation includes daily breathing exercises, mindfulness practices, and vagal nerve-stimulating techniques.
Participants track dadaily behaviors, wellbeing, and wearable data using a billiungual mobile app.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Recruitment Rate (Number of Participants Enrolled per Month)
Tidsramme: From study start (Month 0) to completion of recruitment (approximately Month 12)
|
Number of eligible participants enrolled into the study per month, calculated from the number of participants who consent and complete baseline assessment.
|
From study start (Month 0) to completion of recruitment (approximately Month 12)
|
|
Retention Rate (Percentage of Participants Completing All Study Assessments)
Tidsramme: Baseline to 36 weeks (end of follow-up)
|
Percentage of enrolled participants who complete all four assessment timepoints (baseline, pre-intervention, post-intervention, and 3-month follow-up).
|
Baseline to 36 weeks (end of follow-up)
|
|
Exercise Adherence (Percentage of Completed Scheduled Exercise Sessions)
Tidsramme: Weeks 13-24 (12-week intervention period)
|
Proportion of prescribed exercise sessions attended (twice-weekly supervised sessions) during the 12-week intervention period.
|
Weeks 13-24 (12-week intervention period)
|
|
Mobile Application Engagement (Average Daily Completion Rate of App-Based Logs)
Tidsramme: Weeks 13-24 (12-week intervention period)
|
Average proportion of days participants complete daily logs (including energy, fatigue, mood, sleep, and adherence tracking) via the HEAL MS mobile application.
|
Weeks 13-24 (12-week intervention period)
|
|
Acceptability of HEAL MS Intervention (Participant Satisfaction Score)
Tidsramme: Week 24 (post-intervention assessment)
|
Participant-reported satisfaction with the intervention, assessed using a standardized post-intervention questionnaire (e.g., Likert scale rating of overall experience, usability, and perceived benefit).
|
Week 24 (post-intervention assessment)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Plasma C-Reactive Protein (CRP) Concentration (mg/L)
Tidsramme: Baseline (Week 0), Pre-Intervention (Week 12), Post-Intervention (Week 24), and Follow-up (Week 36)
|
CRP will be measured using standard clinical blood chemistry assays.
Mean change in CRP concentration will be calculated across timepoints to assess systemic inflammation.
|
Baseline (Week 0), Pre-Intervention (Week 12), Post-Intervention (Week 24), and Follow-up (Week 36)
|
|
Change in Plasma Interleukin-6 (IL-6) Levels (pg/mL)
Tidsramme: Baseline (Week 0), Week 12, Week 24, Week 36
|
IL-6 will be quantified using proteomic analysis (Olink platform).
Mean change across timepoints will be used to assess inflammatory signaling.
|
Baseline (Week 0), Week 12, Week 24, Week 36
|
|
Change in Plasma Proteomic Profile (Normalized Protein Expression Units)
Tidsramme: Baseline (Week 0), Week 12, Week 24, Week 36
|
Quantitative proteomic profiling will be performed using the Olink Reveal platform.
A composite score derived from selected proteins related to immune function, oxidative stress, and metabolism will be analyzed using normalized protein expression (NPX) values.
|
Baseline (Week 0), Week 12, Week 24, Week 36
|
|
Change in Circulating Metabolomic Biomarkers (Concentration Units, mmol/L or µmol/L)
Tidsramme: Baseline, Week 12, Week 24, Week 36
|
Metabolomic profiling will be conducted using nuclear magnetic resonance (NMR) spectroscopy, quantifying biomarkers related to lipid metabolism, amino acids, and energy pathways.
Mean changes in selected metabolites will be analyzed.
|
Baseline, Week 12, Week 24, Week 36
|
|
Change in Perceived Stress Score (Perceived Stress Scale, PSS-10)
Tidsramme: Baseline (Week 0), Week 12, Week 24, Week 36
|
Perceived stress will be assessed using the 10-item Perceived Stress Scale (PSS-10), a validated measure of perceived stress over the past month (score range: 0-40; higher scores indicate greater perceived stress).
|
Baseline (Week 0), Week 12, Week 24, Week 36
|
|
Change in Daily Emotional Wellbeing Score (App-Based Self-Assessment)
Tidsramme: Weeks 0, 12, 24, and 36 (7-day averages prior to each assessment)
|
Emotional wellbeing will be assessed using a daily app-based self-report measure (mood and emotional state), collected using a visual Likert or pictorial (Self-Assessment Manikin-style) scale.
Scores will be averaged over 7-day periods prior to each assessment timepoint (range: 0-4; higher scores indicate worse wellbeing).
|
Weeks 0, 12, 24, and 36 (7-day averages prior to each assessment)
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Youssef Idaghdour, Professor, New York University Abu Dhabi
Publikationer og nyttige links
Generelle publikationer
- Simpson-Yap S, Nag N, Probst Y, Reece JC, Jelinek GA, Neate S. Prospective associations of better quality of the diet with improved quality of life over 7.5 years in people with multiple sclerosis. Mult Scler Relat Disord. 2022 Apr;60:103710. doi: 10.1016/j.msard.2022.103710. Epub 2022 Feb 21.
- Nauta IM, Loughlin KNM, Gravesteijn AS, van Wegen J, Hofman RP, Wilmsen N, Coles E, van Kempen ZLE, Killestein J, van Oosten BW, Strijbis EMM, Uitdehaag BMJ, de Jong BA. A multi-domain lifestyle intervention in multiple sclerosis: a longitudinal observational study. J Neurol. 2025 Jun 24;272(7):476. doi: 10.1007/s00415-025-13196-9.
- Sanchez JMS, DePaula-Silva AB, Libbey JE, Fujinami RS. Role of diet in regulating the gut microbiota and multiple sclerosis. Clin Immunol. 2022 Feb;235:108379. doi: 10.1016/j.clim.2020.108379. Epub 2020 Mar 7. No abstract available.
- Mannino A, Lithander FE, Dunlop E, Hoare S, Shivappa N, Daly A, Phillips M, Pereira G, Sherriff J, Lucas RM, Ponsonby AL, Hebert JR, van der Mei I, Black LJ; Ausimmune Investigator Group. A proinflammatory diet is associated with an increased likelihood of first clinical diagnosis of central nervous system demyelination in women. Mult Scler Relat Disord. 2022 Jan;57:103428. doi: 10.1016/j.msard.2021.103428. Epub 2021 Nov 24.
- Coe S, Tektonidis TG, Coverdale C, Penny S, Collett J, Chu BTY, Izadi H, Middleton R, Dawes H. A cross sectional assessment of nutrient intake and the association of the inflammatory properties of nutrients and foods with symptom severity in a large cohort from the UK Multiple Sclerosis Registry. Nutr Res. 2021 Jan;85:31-39. doi: 10.1016/j.nutres.2020.11.006. Epub 2020 Nov 20.
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Sygdomme i nervesystemet
- Patologiske processer
- Metaboliske sygdomme
- Autoimmune sygdomme
- Sygdomme i immunsystemet
- Betændelse
- Demyeliniserende autoimmune sygdomme, CNS
- Autoimmune sygdomme i nervesystemet
- Demyeliniserende sygdomme
- Patologiske tilstande, tegn og symptomer
- Ernæringsmæssige og metaboliske sygdomme
- Tegn og symptomer
- Neuroinflammatoriske sygdomme
- Multipel sclerose
- Træthed
- Multipel sklerose, recidiverende-remitterende
- Mitokondrielle sygdomme
Andre undersøgelses-id-numre
- HRPP-2025-268
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Studiedata/dokumenter
-
Studieprotokol
Oplysningskommentarer: Original Grant Application
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Multipel sclerose
-
Baskent UniversityIkke rekrutterer endnuMULTIPL SKLEROSETyrkiet (Türkiye)
-
City of Hope Medical CenterNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeKlassisk Hodgkin lymfom | Lymfocytrigt klassisk Hodgkin-lymfom | Ann Arbor Stage IB Hodgkin lymfom | Ann Arbor Stage II Hodgkin lymfom | Ann Arbor Stage IIA Hodgkin lymfom | Ann Arbor Stage IIB Hodgkin lymfom | Ann Arbor Stage I Hodgkin lymfom | Ann Arbor Stage I Mixed Cellularity Klassisk Hodgkin-lymfom og andre forholdForenede Stater
Kliniske forsøg med Multi-Domain Lifestyle Intervention
-
Maastricht University Medical CenterIkke rekrutterer endnuBasalcellekarcinom | Optisk kohærenstomografi
-
Maastricht University Medical CenterIkke rekrutterer endnuBasalcellekarcinom
-
National Taiwan Normal UniversityRekrutteringAldring | Motionstræning | Executive funktionTaiwan
-
National Yang Ming Chiao Tung UniversityNational Health Research Institutes, TaiwanRekrutteringAldersrelateret funktionsnedgangTaiwan
-
National Yang Ming UniversityNational Science and Technology CouncilAfsluttetAldersrelateret kognitiv tilbagegang | Aldersrelateret fysiologisk faldTaiwan
-
National Yang Ming UniversityAfsluttet
-
Geriatric Education and Research InstituteNeeuro Pte Ltd; Ministry of Health, Singapore; ProAge Pte Ltd; KKT Technology...AfsluttetKognitiv tilbagegang | Kognitiv svækkelse, mildSingapore
-
The University of Texas Health Science Center,...National Center for Advancing Translational Sciences (NCATS)Aktiv, ikke rekrutterende
-
University of California, San FranciscoNational Heart, Lung, and Blood Institute (NHLBI); Society of Hospital...AfsluttetLungebetændelse | Astma | BronchiolitisForenede Stater
-
Consorzio Futuro in RicercaUniversità degli Studi di Ferrara; Abbott Medical DevicesAktiv, ikke rekrutterendeKoronararteriesygdom | Mikrovaskulær angina | Mikrovaskulær iskæmi af myokardiumItalien